Safety and effectiveness of docetaxel combinated with S-1 for patients with incurable recurrent squamous cell carcinoma of the head and neck
Keywords:
Squamous-cell carcinoma of head and neck, Docetaxel, 5-fluorouracilAbstract
Background and aim of the work: Therapeutic options for patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) are limited. The aim of this study was to determine whether docetaxel (DOC) combined with S-1 (a 5-fluorouracil derivative) is a safe and effective alternative therapy for recurrent, incurable SCCHN that can be administered on an outpatient basis. Methods: We retrospectively investigated the therapeutic outcome and adverse effects of this treatment in 14 patients ineligible for platinum-based therapy because of renal dysfunction, poor overall health, and refractory disease. The patients included 13 men and 1 woman (median age, 64 years; range, 45-79 years). The primary tumor sites were the larynx (n = 6), oropharynx (n = 5), and hypopharynx (n = 3). DOC was administered intravenously for 3-4 weeks at 20-30 mg/m2, and S-1 was administered orally twice daily for 2 weeks at 80-120 mg/day followed by rest for 1-2 weeks. Results: Grade ≤2 hematotoxicity manifesting as leukopenia (n = 3), neutropenia (n = 2), and anemia (n = 4) was observed. Non-hematotoxic adverse effects were grade 2 fatigue (n = 2) and anorexia (n = 1); 1 patient had a grade 4 anaphylactic reaction. The median survival time was 10 months; survival rates after 6 months and 1 year were 64.3% and 32.7%, respectively. Conclusions: The DOC and S-1 regimen caused mild adverse effects and is therefore feasible for ambulatory administration as a salvage treatment for SCCHN patients ineligible for platinum-based chemotherapy.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.